Education
About Us
Working with TipRanks
Follow Us
Veru (VERU)
NASDAQ:VERU
VERU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.45 - $1.75
Previous CloseN/A
Volume1.22M
Average Volume (3M)1.83M
Market Cap
$76.92M
Enterprise Value$107.68M
Total Cash (Recent Filing)$5.17M
Total Debt (Recent Filing)$20.02K
Price to Earnings (P/E)―
Beta0.30
Next Earnings
May 07, 2025EPS Estimate
-0.06Last Dividend Ex-Date
Apr 28, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding146,383,930
10 Day Avg. Volume1,700,532
30 Day Avg. Volume1,827,343
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.13
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit18.39
Enterprise Value/Ebitda-2.76
Forecast
1Y Price Target
$4.50Price Target Upside765.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Veru News
PremiumCompany Announcements
Veru Inc. Shareholders Approve Equity Plan Amendment
PremiumCompany Announcements
Veru Inc. Reports Strong Q1 Results and Clinical Progress
PremiumCompany Announcements
Veru Inc Earnings Call: Clinical Wins Amid Financial Concerns---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe Ph. IIb QUALITY study has achieved full enrollment of over 150 patients, with top-line data expected to provide insights into enobosarm's effectiveness.
Product DifferentiationEnobosarm's selective targeting of musculoskeletal androgen receptors differentiates it from other treatments, reducing negative effects associated with testosterone and anabolic steroids.
Strategic Business FocusVERU has strategically monetized its FC2 female condom business for $18M to focus solely on enobosarm's development.
Bears Say
Financial OutlookThe company may need to raise additional capital within the next 12 months, in our view.
Initial Trial ResultsA significant intra-day stock sell-off was attributed to the lack of meaningful weight loss benefits observed during the initial period of the study.
---
Ownership Overview
10.57% Insiders
6.47% Mutual Funds
0.45% Other Institutional Investors
72.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VERU FAQ
What was Veru’s price range in the past 12 months?
Veru lowest stock price was $0.45 and its highest was $1.75 in the past 12 months.
What is Veru’s market cap?
Veru’s market cap is $76.92M.
When is Veru’s upcoming earnings report date?
Veru’s upcoming earnings report date is May 07, 2025 which is in 19 days.
How were Veru’s earnings last quarter?
Veru released its earnings results on Feb 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.076 by $0.016.
Is Veru overvalued?
According to Wall Street analysts Veru’s price is currently Undervalued.
Does Veru pay dividends?
Veru pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru dividends here
What is Veru’s EPS estimate?
Veru’s EPS estimate is -0.06.
How many shares outstanding does Veru have?
Veru has 146,383,930 shares outstanding.
What happened to Veru’s price movement after its last earnings report?
Veru reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.076. Following the earnings report the stock price went down -5.455%.
Which hedge fund is a major shareholder of Veru?
Currently, no hedge funds are holding shares in VERU
---
Veru Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (765.38% Upside)
$4.50 (765.38% Upside)
Blogger Sentiment
Bullish
VERU Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 869.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $84.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.16%
12-Months-Change
Fundamentals
Return on Equity
-80.11%
Trailing 12-Months
Asset Growth
-50.56%
Trailing 12-Months
Company Description
Veru
Veru Inc. (VERU) is a biopharmaceutical company focused on developing novel medicines for the management of cancers. The company operates primarily in the pharmaceutical sector, with a strong emphasis on oncology and urology. Its core products and services include proprietary drugs for the treatment of prostate cancer and breast cancer, as well as sexual health products.
---
VERU Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials with enobosarm, showcasing positive results in muscle preservation and fat loss. The strategic sale of the FC2 business and financial gains from debt extinguishment were also notable. However, financial challenges such as the loss on sale of the FC2 business, increased R&D costs, negative cash flow, and limited cash runway were concerning.Read More>---
VERU Stock 12 Month Forecast
Average Price Target
$4.50
▲(765.38% Upside)
Technical Analysis
Best Analysts Covering VERU
1 Year
1 Year Success Rate
12/33 ratings generated profit
1 Year Average Return
+7.00%
reiterated a buy rating 2 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of +7.00% per trade.
---